Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
Digital
- Autores:
-
Guzik, Tomasz J.
Ramasundarahettige, Chinthanie
Pogosova, Nana
Lopez-Jaramillo, Patricio
Dyal, Leanne
Berkowitz, Scott D.
Muehlhofer, Eva
Bhatt, Deepak L.
Fox, Keith A.
Yusuf, Salim
Eikelboom, John W.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6128
- Acceso en línea:
- https://doi.org/10.1016/j.jacc.2020.11.061
https://repositorio.udes.edu.co/handle/001/6128
- Palabra clave:
- Rights
- openAccess
- License
- Copyright © 2021, The Authors, American College of Cardiology Foundation. Published by Elsevier
| id |
RUDES2_eca3f93b0a0b83bbd6e11960ff81c5d7 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/6128 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| title |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| spellingShingle |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| title_short |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| title_full |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| title_fullStr |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| title_full_unstemmed |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| title_sort |
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial |
| dc.creator.fl_str_mv |
Guzik, Tomasz J. Ramasundarahettige, Chinthanie Pogosova, Nana Lopez-Jaramillo, Patricio Dyal, Leanne Berkowitz, Scott D. Muehlhofer, Eva Bhatt, Deepak L. Fox, Keith A. Yusuf, Salim Eikelboom, John W. |
| dc.contributor.author.none.fl_str_mv |
Guzik, Tomasz J. Ramasundarahettige, Chinthanie Pogosova, Nana Lopez-Jaramillo, Patricio Dyal, Leanne Berkowitz, Scott D. Muehlhofer, Eva Bhatt, Deepak L. Fox, Keith A. Yusuf, Salim Eikelboom, John W. |
| dc.contributor.researchgroup.spa.fl_str_mv |
Masira |
| description |
Digital |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021-02-05 |
| dc.date.accessioned.none.fl_str_mv |
2022-02-23T16:08:53Z |
| dc.date.available.none.fl_str_mv |
2022-02-23T16:08:53Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.jacc.2020.11.061 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6128 |
| url |
https://doi.org/10.1016/j.jacc.2020.11.061 https://repositorio.udes.edu.co/handle/001/6128 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
525 |
| dc.relation.citationissue.spa.fl_str_mv |
5 |
| dc.relation.citationstartpage.spa.fl_str_mv |
511 |
| dc.relation.citationvolume.spa.fl_str_mv |
77 |
| dc.relation.cites.none.fl_str_mv |
Tomasz J. Guzik, Chinthanie Ramasundarahettige, Nana Pogosova, Patricio Lopez-Jaramillo, Leanne Dyal, Scott D. Berkowitz, Eva Muehlhofer, Deepak L. Bhatt, Keith A.A. Fox, Salim Yusuf, John W. Eikelboom, Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial, Journal of the American College of Cardiology, Volume 77, Issue 5, 2021, Pages 511-525, ISSN 0735-1097, https://doi.org/10.1016/j.jacc.2020.11.061. (https://www.sciencedirect.com/science/article/pii/S0735109720380049) |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Journal of the American College of Cardiology |
| dc.rights.spa.fl_str_mv |
Copyright © 2021, The Authors, American College of Cardiology Foundation. Published by Elsevier |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Copyright © 2021, The Authors, American College of Cardiology Foundation. Published by Elsevier Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
15 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
JACC Journals |
| dc.publisher.place.spa.fl_str_mv |
USA |
| dc.source.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0735109720380049?via%3Dihub |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/75b48a65-5eb8-48dc-83c6-3fde2230a7b6/download https://repositorio.udes.edu.co/bitstreams/204c9d5b-b519-4ae9-93e3-fcedafdc3efd/download https://repositorio.udes.edu.co/bitstreams/e5baa5b5-a3ea-4e35-add4-6996ccf315cb/download https://repositorio.udes.edu.co/bitstreams/7db0d7b6-ac64-4ff1-91e2-c704f46992dd/download |
| bitstream.checksum.fl_str_mv |
480ea17891998028d5a082e3a6332ff5 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 713aba2623d231534f119ca134a9a16a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814158619416985600 |
| spelling |
Guzik, Tomasz J.89522b4a-0787-4c77-b1b5-c17e263b9f07-1Ramasundarahettige, Chinthanie76b2878f-0db1-4aaa-b925-598d763e666c-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Dyal, Leanne2c1519ed-7131-4c64-ae64-60293a636b7c-1Berkowitz, Scott D.ec037f48-fc80-4c5b-ac4b-721684ff8fc4-1Muehlhofer, Eva5a886438-9d49-4a24-a49d-8095c6996616-1Bhatt, Deepak L.a6b9f89b-fac3-41d8-9b27-b1ef9e6add0c-1Fox, Keith A.346a05ff-d114-4673-bafe-56302d12a6c3-1Yusuf, Salim06a836b5-f5e3-41d9-a516-9cc46e5d7948-1Eikelboom, John W.811d3edf-9c24-4953-89ed-c764e4f98190-1Masira2022-02-23T16:08:53Z2022-02-23T16:08:53Z2021-02-05DigitalBackground Direct oral anticoagulants are administered in fixed doses irrespective of body weight, but guidelines recommend against their use in patients with extremes of body weight. Objectives This study determined the effects of dual-pathway inhibition antithrombotic regimen (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day) compared with aspirin Halone across a range of patient body mass indexes (BMIs) and body weights. Methods This was a secondary analysis of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, which included patients with chronic coronary artery disease or peripheral artery disease. Efficacy and safety outcomes were studied in relation to BMI: (normal 18.5 ≤BMI <25 kg/m2, overweight 25 ≤BMI <30 kg/m2, obese ≥30 kg/m2) and body weight (≤70 kg, 70 < weight ≤90 kg, and >90 kg; as well as ≤120 kg vs. >120 kg). Results Among 27,395 randomized patients, 6,459 (24%) had normal BMI, 12,047 (44%) were overweight, and 8,701 (32%) were obese. The combination of rivaroxaban and aspirin compared with aspirin produced a consistent reduction in the primary outcome of cardiovascular death, stroke, or myocardial infarction, irrespective of BMI or body weight. For 18.5 ≤BMI <25 kg/m2: 3.5% vs. 5.0%; hazard ratio (HR): 0.73 (95% credible interval [CrI]: 0.58 to 0.90); 25 ≤ BMI <30 kg/m2: 4.3% vs. 5.1%; HR: 0.80 (95% CrI: 0.66 to 0.96); BMI ≥30 kg/m2: 4.2% vs. 6.1%; HR: 0.71 (95% CrI: 0.57 to 0.86). For body weight ≤70 kg: 4.1% vs. 5.3%; HR: 0.75 (95% CrI: 0.62 to 0.91); 70 < weight ≤90 kg: 4.1% vs. 5.3%; HR: 0.76 (95% CrI: 0.65 to 0.89); >90 kg: 4.2% vs. 5.7%; HR: 0.74 (95% CrI: 0.61 to 0.90). Effects on bleeding, mortality, and net clinical benefit were consistent irrespective of BMI or bodyweight. Conclusions The effects of dual-pathway antithrombotic therapy are consistent irrespective of BMI or body weight, suggesting no need for dose adjustments in the ranges of weights and BMI of patients enrolled in the COMPASS trial. Further studies need to address this problem in relation to greater extremes of body weight. (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424)Ciencias Médicas y de la Salud15 papplication/pdfhttps://doi.org/10.1016/j.jacc.2020.11.061https://repositorio.udes.edu.co/handle/001/6128engJACC JournalsUSA525551177Tomasz J. Guzik, Chinthanie Ramasundarahettige, Nana Pogosova, Patricio Lopez-Jaramillo, Leanne Dyal, Scott D. Berkowitz, Eva Muehlhofer, Deepak L. Bhatt, Keith A.A. Fox, Salim Yusuf, John W. Eikelboom, Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial, Journal of the American College of Cardiology, Volume 77, Issue 5, 2021, Pages 511-525, ISSN 0735-1097, https://doi.org/10.1016/j.jacc.2020.11.061. (https://www.sciencedirect.com/science/article/pii/S0735109720380049)ScopusJournal of the American College of CardiologyCopyright © 2021, The Authors, American College of Cardiology Foundation. Published by Elsevierinfo:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.sciencedirect.com/science/article/pii/S0735109720380049?via%3DihubRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS TrialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.pdfRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.pdfapplication/pdf228081https://repositorio.udes.edu.co/bitstreams/75b48a65-5eb8-48dc-83c6-3fde2230a7b6/download480ea17891998028d5a082e3a6332ff5MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/204c9d5b-b519-4ae9-93e3-fcedafdc3efd/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.pdf.txtRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/e5baa5b5-a3ea-4e35-add4-6996ccf315cb/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.pdf.jpgRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.pdf.jpgGenerated Thumbnailimage/jpeg11770https://repositorio.udes.edu.co/bitstreams/7db0d7b6-ac64-4ff1-91e2-c704f46992dd/download713aba2623d231534f119ca134a9a16aMD54001/6128oai:repositorio.udes.edu.co:001/61282023-10-09 16:45:37.526https://creativecommons.org/licenses/by-nc/4.0/Copyright © 2021, The Authors, American College of Cardiology Foundation. Published by Elsevierhttps://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |